ICAM1 and neoplasm: From a therapeutic standpoint, considering the multiple intercellular interactions ICAM1 may mediate in tumor initiation and metastasis, we expect that the anti-ICAM1 blockade approach can potentially be added to a combination with other existing therapeutics for TNBC, such as chemotherapeutic agents, PARP inhibitors, anti-vascular reagents, and possibly immunotherapy.